Login / Signup

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.

Debbie G J RobbrechtJuanita LopezEmiliano CalvoXiaomin HeHirai HiroshiNital SoniNatalie CookAfshin DowlatiAngelica FasoloVictor MorenoFerry A L M EskensJohann S de Bono
Published in: British journal of cancer (2020)
NCT02448589.
Keyphrases
  • endothelial cells
  • induced pluripotent stem cells